MCA logo



Semaglutide (Rybelsus®) receives FDA approval as first line treatment for Type 2 Diabetes Mellitus

Novo Nordisk
Semaglutide, available in oral and subcutaneous dosage forms, is a selective glucagon-like peptide-1 receptor agonist with 3 main mechanisms of action.

Sign Up or Log In as a healthcare professional to read the full article.

Share via

Also worth reading

People also read:

Weekly Asian Bulletin 19 May 2023 – Heatwave edition

Medical Channel Asia presents the weekly Asian medical news bulletin, bringing you essential healthcare news from across the region. Asia finds itself gripped by an unprecedented heatwave, with soaring temperatures marking record highs not seen in decades. This week’s bulletin will focus on heat-related news across the region.

Read More »